Latest Breast Updates from June 2007 ASCO Conference
Published: Fri Apr 29, 2011 Updated:Wed Sep 14, 2011We would like to thank Drs Sunil Verma & Christine Simmons for providing us with the latest oncology breast conference updates.
Phase III trial of ixabepilone plus capecitabine compared to capecitabine alone in patients with metastatic breast cancer (MBC) previously treated or resistant to an anthracycline and resistant to taxanes
A randomized trial of capecitabine given intermittently rather than continously compared to classical CMF as first line chemotherapy for advanced breast cancer
Updated results on the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with Her-2 positive breast cancer
Five Year Update of Cardiac Dysfunction in NSABP B-31: A Randomized Trial of AC→ Paclitaxel vs. AC→ Paclitaxel with Trastuzumab in HER2- Postive, Node Positive, Operable Breast Cancer
Lapatinib (L) with paclitaxel compared to paclitaxel as first-line treatment for patients with metastatic breast cancer: A phase III randomized, double-blind study of 580 patients
Changes in estrogen receptor (ER), progesterone receptor (PR) and HER2/neu status with time: Discordance rates between primary and metastatic breast pathology samples
